| Original language | English (US) |
|---|---|
| Pages (from-to) | e126-e129 |
| Journal | Haemophilia |
| Volume | 25 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 2019 |
All Science Journal Classification (ASJC) codes
- Hematology
- Genetics(clinical)
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Factor IX inhibitors : Clinical and laboratory profiles of two patients with severe haemophilia B. / Saini, Surbhi; Croteau, Stacy E.; Horling, Frank M.; Dunn, Amy L.
In: Haemophilia, Vol. 25, No. 2, 03.2019, p. e126-e129.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Factor IX inhibitors
T2 - Clinical and laboratory profiles of two patients with severe haemophilia B
AU - Saini, Surbhi
AU - Croteau, Stacy E.
AU - Horling, Frank M.
AU - Dunn, Amy L.
N1 - Funding Information: ALD reports grants, personal fees and non‐financial support from Bayer; grants and personal fees from Bioverativ; grants, personal fees and non‐financial support from CSL Behring; grants, personal fees and non‐financial support from Pfizer; grants, personal fees and non‐financial support from Shire; personal fees and non‐fi‐ nancial support from Medscape; grants, personal fees and non‐fi‐ nancial support from Hema Biologics; grants from Alnylam; grants from Octapharma; personal fees and non‐financial support from NovoNordisk; other from LittleSeed Inc. SEC reports institutional research funds from Pfizer, Spark Therapeutics, Genentech, and Boehringer Ingelheim, and consulting fees or honoraria from Bayer, Biomarin, Bioveritiv, Catalyst Biosciences, CSL‐Behring, Genentech, Novo Nordisk, and Octapharma. FMH was an em‐ ployee of Shire until 06/2018. SS declared that there is no conflict of interest. Funding Information: ALD and SEC designed the research; SS and SEC collected the clini‐ cal data; FMH performed the laboratory analysis; SS drafted the initial manuscript, and reviewed and revised the manuscript; ALD, SEC and FMH reviewed and revised the manuscript. SS reports no competing interests. SEC reports institutional research funds from Pfizer, Spark Therapeutics, Genentech and Boehringer Ingelheim, and consulting fees or honoraria from Bayer, Biomarin, Bioveritiv, Catalyst Biosciences, CSL Behring, Genentech, Novo Nordisk and Octapharma. FMH was an employee of Shire until June 2018. ALD reports grants, personal fees and non‐financial support from Bayer, grants and personal fees from Bioverativ, grants, personal fees and non‐financial support from CSL Behring, grants, personal fees and non‐financial support from Pfizer, grants, personal fees and non‐financial support from Shire, personal fees and non‐fi‐ nancial support from Medscape, grants, personal fees and non‐fi‐ nancial support from Hema Biologics, grants from Alnylam, grants from Octapharma, personal fees and non‐financial support from NovoNordisk, during the conduct of the study; other from Little Seed Inc
PY - 2019/3
Y1 - 2019/3
UR - http://www.scopus.com/inward/record.url?scp=85062322324&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062322324&partnerID=8YFLogxK
U2 - 10.1111/hae.13696
DO - 10.1111/hae.13696
M3 - Letter
C2 - 30817051
AN - SCOPUS:85062322324
VL - 25
SP - e126-e129
JO - Haemophilia
JF - Haemophilia
SN - 1351-8216
IS - 2
ER -